These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23939237)

  • 21. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
    Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.
    van der Straten A; Van Damme L; Haberer JE; Bangsberg DR
    AIDS; 2012 Apr; 26(7):F13-9. PubMed ID: 22333749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
    Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sönnerborg A; Nachega JB
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S101-6. PubMed ID: 23687287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
    Abbas UL; Glaubius R; Mubayi A; Hood G; Mellors JW
    J Infect Dis; 2013 Jul; 208(2):224-34. PubMed ID: 23570850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute HIV at the Time of Initiation of Pre-exposure or Post-exposure Prophylaxis: Impact on Drug Resistance and Clinical Outcomes.
    Johnson KA; Chen MJ; Kohn R; Sachdev D; Bacon O; Lee S; Cohen SE
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):818-825. PubMed ID: 33512849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA treads carefully with PrEP.
    Holmes D
    Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826
    [No Abstract]   [Full Text] [Related]  

  • 30. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(23):463-5. PubMed ID: 23760186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When is good good enough for HIV-1 prophylaxis?
    Buchbinder S
    Lancet Infect Dis; 2014 Nov; 14(11):1024-1025. PubMed ID: 25300861
    [No Abstract]   [Full Text] [Related]  

  • 33. Ethics and pre-exposure prophylaxis for HIV infection.
    Sugarman J; Mayer KH
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
    Mayer KH; Mimiaga MJ; Gelman M; Grasso C
    J Acquir Immune Defic Syndr; 2012 Apr; 59(4):354-9. PubMed ID: 22267017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
    Thigpen MC; Kebaabetswe PM; Paxton LA; Smith DK; Rose CE; Segolodi TM; Henderson FL; Pathak SR; Soud FA; Chillag KL; Mutanhaurwa R; Chirwa LI; Kasonde M; Abebe D; Buliva E; Gvetadze RJ; Johnson S; Sukalac T; Thomas VT; Hart C; Johnson JA; Malotte CK; Hendrix CW; Brooks JT;
    N Engl J Med; 2012 Aug; 367(5):423-34. PubMed ID: 22784038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
    Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
    J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022.
    Misra K; Huang JS; Udeagu CN; Forgione L; Xia Q; Torian LV
    Clin Infect Dis; 2024 May; 78(5):1240-1245. PubMed ID: 37976185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preexposure chemoprophylaxis for HIV prevention.
    Pimpinella G; Malgarini RB
    N Engl J Med; 2011 Apr; 364(14):1373; author reply 1374-5. PubMed ID: 21470024
    [No Abstract]   [Full Text] [Related]  

  • 40. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.